Zentalis Pharmaceuticals (ZNTL) EBT (2019 - 2026)
Zentalis Pharmaceuticals' quarterly EBT came in at -$35.2 million in Q1 2026, up 27.02% year-on-year from -$27.7 million in Q1 2025, and down 1.32% quarter-over-quarter from -$34.8 million in Q4 2025.
Zentalis Pharmaceuticals has reported EBT for 8 years, with the latest figure at -$35.2 million in Q1 2026.
- For the quarter ending Q1 2026, EBT rose 27.02% year-over-year to -$35.2 million; the trailing twelve-month figure through Mar 2026 stood at -$123.6 million (up 44.87% YoY), and the FY2025 full-year result was -$136.6 million, up 17.55% from the prior year.
- EBT for Q1 2026 stood at -$35.2 million, down from -$34.8 million in the prior quarter.
- The five-year high for EBT was $10.2 million in Q1 2024, with the low at -$99.5 million in Q2 2023.
- Average EBT over 5 years is -$49.2 million, with a median of -$48.5 million recorded in 2022.
- Year-over-year, EBT surged 116.74% in 2024 and slumped 574.11% in 2025.
- Tracing ZNTL's EBT over 5 years: stood at -$48.5 million in 2022, then retreated by 25.87% to -$61.1 million in 2023, then increased by 21.94% to -$47.7 million in 2024, then climbed by 27.06% to -$34.8 million in 2025, then fell by 1.32% to -$35.2 million in 2026.
- The last three EBT figures came in at -$35.2 million (Q1 2026), -$34.8 million (Q4 2025), and -$26.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | -35.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.23 Mn |
| Dec 31, 2025 | -34.77 Mn |
| Sep 30, 2025 | -26.69 Mn |
| Jun 30, 2025 | -26.87 Mn |
| Mar 31, 2025 | -48.28 Mn |
| Dec 31, 2024 | -47.68 Mn |
| Sep 30, 2024 | -40.19 Mn |
| Jun 30, 2024 | -88.01 Mn |
| Mar 31, 2024 | 10.18 Mn |
| Dec 31, 2023 | -61.07 Mn |
| Sep 30, 2023 | -55.51 Mn |
| Jun 30, 2023 | -99.47 Mn |
| Mar 31, 2023 | -60.84 Mn |
| Dec 31, 2022 | -48.52 Mn |
| Sep 30, 2022 | -52.29 Mn |
| Jun 30, 2022 | -63.04 Mn |
| Mar 31, 2022 | -57.45 Mn |
| Dec 31, 2021 | -48.11 Mn |
| Sep 30, 2021 | -11.19 Mn |
| Jun 30, 2021 | -55.02 Mn |
| Mar 31, 2021 | -50.25 Mn |
| Dec 31, 2020 | -39.93 Mn |
| Sep 30, 2020 | -34.65 Mn |
| Jun 30, 2020 | -27.29 Mn |
| Mar 31, 2020 | -16.24 Mn |
| Dec 31, 2019 | -14.55 Mn |
| Sep 30, 2019 | -12.57 Mn |
| Jun 30, 2019 | -10.59 Mn |
| Mar 31, 2019 | -8.66 Mn |